Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
NEW YORK, March 22, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) securities between March 5, 2015 and September 8, 2015.
Click here to learn about the case: http://docs.wongesq.com/TTPH-Info-Request-Form-1089. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/TTPH-Info-Request-Form-1089.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
